15 OPEN-LABEL PROSPECTIVE RANDOMIZED 48 WEEK CLINICAL TRIAL: ROSIGLITAZONE VERSUS ROSIGLITAZONE AND METFORMIN (AVANDAMET) VERSUS ROSIGLITAZONE AND LOSARTAN IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH)

Rosiglitazone versus rosiglitazone and m

Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12-month randomized, prospective, open- label trial

✍ Dawn M. Torres; Frances J. Jones; Janet C. Shaw; Christopher D. Williams; John A 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 393 KB

Medication combinations that improve the efficacy of thiazolidinediones or ameliorate weight-gain side effects of therapy represent an attractive potential treatment for (NASH). The aim of this randomized, open-label trial was to assess the efficacy of rosiglitazone and metformin in combination vers